Traditional companies focus their innovative efforts on the discovery of new drugs that save and improve lives. Apobiologix sees a need to go further: to create sustainable health care that doesn't sacrifice quality or patient support. That's why biosimilars also require innovation.
Apobiologix is focused on the development of biosimilars that combine the quality and value you need with the level of comprehensive support you expect.
Because at Apobiologix, we don't believe that innovation stops at invention.
Apobiologix has experience in the successful development and marketing of biosimilar products. In October 2013, Grastofil (filgrastim) was launched in the EU for all approved uses of its innovator biologic.
Key areas of focus include:
2400 North Commerce Parkway,
Weston, Florida 33326
Grastofil™ is a trademark of Apotex Technologies Inc. Neupogen® and Neulasta® are registered trademarks of Amgen.